Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases. Clementia exploits the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.
Investment year: 2012
Industry sector: Drugs
Canada’s biotech sector continues to build momentum with two large IPOs since March